


PHARMACEUTICAL 2022



Bolt Biotherapeutics Inc. Rank 168 of 466





PHARMACEUTICAL 2022



Bolt Biotherapeutics Inc. Rank 168 of 466

The relative strengths and weaknesses of Bolt Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bolt Biotherapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Bolt Biotherapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 104% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	189,160
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,328
Liabilities, Non-Current	22,064
Other Assets	112,400
Other Compr. Net Income	-321
Other Expenses	0
Other Liabilities	14,207
Other Net Income	-5,803
Other Revenues	1,260
Property and Equipment	6,158
Research and Development	75,655
Selling, General and Administrative Expense	18,393

Output Variable	Value in 1000 USD
Assets	307,718
Liabilities	57,599
Expenses	94,048
Revenues	1,260
Stockholders Equity	250,119
Net Income	-98,591
Comprehensive Net Income	-98,752
Economic Capital Ratio	181%

